| Segment, Geographic and Other Revenue Information | Segment, Geographic and Other Revenue Information A. Segment Information At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of three distinct business segments: Biopharma, Upjohn and through July 31, 2019, Pfizer’s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is, and through July 31, 2019 Consumer Healthcare was, responsible for its own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. Acquisitions and other business development activities completed in 2019 and in the first nine months of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented. See Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, and Note 2. Operating Segments Some additional information about our Biopharma and Upjohn business segments follows: Pfizer Biopharmaceuticals Group Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients’ lives. Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone. Select products include: - Prevnar 13/Prevenar 13 - Ibrance - Eliquis - Xeljanz - Enbrel (outside the U.S. and Canada) - Vyndaqel/Vyndamax - Xtandi - Chantix/Champix - Sutent Select products include: - Lipitor - Lyrica - Celebrex - Viagra - Certain generic medicines Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRDM––the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines. • GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies. • Other––the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization. • Corporate and Other Unallocated––the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled; therefore, such information is not presented. Selected Income Statement Information The following summarizes selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 27, September 29, September 27, September 29, Reportable Segments: Biopharma $ 10,215 $ 9,952 $ 6,807 $ 6,506 Upjohn 1,916 2,351 1,009 1,384 Total reportable segments 12,131 12,303 7,816 7,890 Other business activities — 377 (1,939) (1,469) Reconciling Items: Corporate and other unallocated — — (1,192) (1,439) Purchase accounting adjustments — — (823) (1,141) Acquisition-related costs — — (11) (300) Certain significant items (b) — — (1,675) 7,187 $ 12,131 $ 12,680 $ 2,176 $ 10,727 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) September 27, September 29, September 27, September 29, Reportable Segments: Biopharma $ 30,017 $ 28,429 $ 20,186 $ 18,461 Upjohn 5,944 8,535 3,367 5,635 Total reportable segments 35,961 36,964 23,554 24,096 Other business activities — 2,098 (4,958) (3,776) Reconciling Items: Corporate and other unallocated — — (3,437) (4,116) Purchase accounting adjustments — — (2,545) (3,357) Acquisition-related costs — — (46) (152) Certain significant items (b) — — (2,554) 6,495 $ 35,961 $ 39,062 $ 10,014 $ 19,190 (a) Income from continuing operations before provision/(benefit) for taxes on income . Biopharma’s earnings include dividend income of $44 million in the third quarter of 2020 and $43 million in the third quarter of 2019, and $196 million in the first nine months of 2020 and $184 million in the first nine months of 2019 from our investment in ViiV. See Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. In the third quarter and first nine months of 2020, includes, among other items, intangible asset impairment charges of $900 million, recorded in Other (income)/deductions—net, related to IPR&D assets acquired in connection with our Array acquisition. In the third quarter and first nine months of 2019, includes, among other items, a pre-tax gain of $8.1 billion recorded in (Gain) on completion of Consumer Healthcare JV transaction associated with the completion of the GSK Consumer Healthcare joint venture transaction ( See Note 2 ). Certain significant items are discussed further in Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information The following summarizes revenues by geographic area: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) September 27, September 29, % September 27, September 29, % United States $ 5,716 $ 5,850 (2) $ 16,770 $ 18,360 (9) Developed Europe (a) 2,087 2,135 (2) 6,095 6,450 (5) Developed Rest of World 1,634 1,585 3 4,642 4,758 (2) Emerging Markets 2,694 3,110 (13) 8,453 9,493 (11) Revenues $ 12,131 $ 12,680 (4) $ 35,961 $ 39,062 (8) (a) Revenues denominated in euros were $1.7 billion in the third quarter of 2020 and $1.7 billion in the third quarter of 2019, and were $4.9 billion in the first nine months of 2020 and $5.2 billion in the first nine months of 2019. C. Other Revenue Information Significant Product Revenues The following provides detailed revenue information for several of our major products: (MILLIONS OF DOLLARS) Three Months Ended Nine Months Ended PRODUCT PRIMARY INDICATION OR CLASS Sept. 27, 2020 Sept. 29, 2019 Sept. 27, 2020 Sept. 29, 2019 TOTAL REVENUES $ 12,131 $ 12,680 $ 35,961 $ 39,062 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) $ 10,215 $ 9,952 $ 30,017 $ 28,429 Internal Medicine (a) $ 2,085 $ 2,128 $ 6,695 $ 6,508 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,114 1,025 3,686 3,121 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 223 276 728 825 Premarin family Symptoms of menopause 168 182 471 542 BMP2 Development of bone and cartilage 70 66 197 212 Toviaz Overactive bladder 59 61 183 186 All other Internal Medicine Various 451 517 1,429 1,621 Oncology $ 2,761 $ 2,350 $ 7,843 $ 6,547 Ibrance Metastatic breast cancer 1,357 1,283 3,955 3,677 Xtandi alliance revenues mCRPC, nmCRPC, mCSPC 266 225 741 594 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 202 224 616 704 Inlyta Advanced RCC 195 139 559 316 Xalkori ALK-positive and ROS1-positive advanced NSCLC 122 130 409 385 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 111 90 324 267 Retacrit (b) Anemia 102 64 278 147 Lorbrena ALK-positive metastatic NSCLC 55 32 142 77 Braftovi In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy 42 18 116 18 Mektovi In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation 34 19 103 19 (MILLIONS OF DOLLARS) Three Months Ended Nine Months Ended PRODUCT PRIMARY INDICATION OR CLASS Sept. 27, 2020 Sept. 29, 2019 Sept. 27, 2020 Sept. 29, 2019 Ruxience (b) Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis 59 — 78 — All other Oncology Various 217 125 522 342 Hospital (a), (c) $ 1,728 $ 1,840 $ 5,535 $ 5,505 Sulperazon Bacterial infections 143 163 432 505 Medrol Anti-inflammatory glucocorticoid 87 109 295 348 Zithromax Bacterial infections 25 77 218 254 Precedex Sedation agent in surgery or intensive care 55 36 211 116 Vfend Fungal infections 52 87 201 265 Panzyga Primary humoral immunodeficiency 62 46 199 107 Fragmin Treatment/prevention of venous thromboembolism 60 62 178 185 Zyvox Bacterial infections 51 61 176 195 Pfizer CentreOne (d) Various 242 176 618 556 All other Anti-infectives Various 384 434 1,195 1,260 All other Hospital (c) Various 568 589 1,813 1,713 Vaccines $ 1,717 $ 1,808 $ 4,574 $ 4,795 Prevnar 13/Prevenar 13 Pneumococcal disease 1,534 1,603 4,100 4,268 Nimenrix Meningococcal disease 50 52 180 159 FSME/IMMUN-TicoVac Tick-borne encephalitis disease 77 64 170 197 All other Vaccines Various 56 89 124 171 Inflammation & Immunology (I&I) $ 1,173 $ 1,226 $ 3,299 $ 3,482 Xeljanz RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis 654 599 1,741 1,634 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 321 415 1,005 1,285 Inflectra/Remsima (b) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 162 155 471 446 All other I&I Various 35 58 83 116 Rare Disease $ 752 $ 601 $ 2,071 $ 1,592 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 351 156 859 259 BeneFIX Hemophilia B 107 125 337 372 Genotropin Replacement of human growth hormone 107 124 316 357 Refacto AF/Xyntha Hemophilia A 92 104 272 319 Somavert Acromegaly 67 64 198 192 All other Rare Disease Various 27 28 89 94 UPJOHN (a) $ 1,916 $ 2,351 $ 5,944 $ 8,535 Lipitor Reduction of LDL cholesterol 356 476 1,191 1,506 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 352 527 1,058 2,888 Norvasc Hypertension 183 219 601 735 Celebrex Arthritis pain and inflammation, acute pain 133 179 428 526 Viagra Erectile dysfunction 121 120 342 379 Effexor Depression and certain anxiety disorders 80 80 242 242 Zoloft Depression and certain anxiety disorders 76 74 233 217 EpiPen (a) Epinephrine injection used in treatment of life-threatening allergic reactions 58 74 194 197 Xalatan/Xalacom Glaucoma and ocular hypertension 62 68 188 201 Xanax Anxiety disorders 55 50 149 147 All other Upjohn Various 442 485 1,317 1,496 CONSUMER HEALTHCARE BUSINESS (e) $ — $ 377 $ — $ 2,098 Total Alliance revenues $ 1,250 $ 1,141 $ 4,036 $ 3,418 Total Biosimilars (b) $ 424 $ 236 $ 1,001 $ 632 Total Sterile Injectable Pharmaceuticals (f) $ 1,195 $ 1,248 $ 3,839 $ 3,703 (a) Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation. (b) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit and Ruxience. (c) Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (d) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements. (e) On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. See Note 2B . (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals. |
